Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. META
10. TLT

Go back to Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update

UBS Starts Insmed (INSM) at Buy, 'We see ~60% upside to the current share price'

February 26, 2024 4:22 PM EST

UBS analyst Trung Huynh initiates coverage on Insmed (NASDAQ: INSM) with a Buy rating and a price target of $46.00.

The analyst comments "We are initiating on INSM with a Buy rating and $46 PT. INSM is a commercial-stage biotech developing therapies for pulmonary... More